Press "Enter" to skip to content

Array BioPharma’s colorectal cancer combo treatment meets main goals

The combination therapy, comprising Array’s Braftovi and Mektovi and Eli Lilly and Co’s Erbitux, helped half the patients enrolled in the study survive nine months.

Original source:

Also Read:   Lupin developing new products to treat cancer, other diseases